Lundquist Institute Investigator Eiji Yoshihara, PhD., receives Internationally Prestigious Award for Research on Type 1 Diabetes

Related coverage

• The Lundquist Institute · Apr 1, 2024 Lundquist investigator Dr. Eiji Yoshihara awarded $3 million NIH R01 grant for diabetes stem cell therapy research

  Dr. Yoshihara's research focuses on creating functional islet cells using human pluripotent stem cells to treat insulin-dependent diabetes. The goal is to overcome the limitations of current stem cell-derived organoids and accelerate their maturation through cutting-edge transcriptional gene regulation processes.

• The Lundquist Institute · Apr 24, 2024 The Lundquist Institute receives $2.6 million grant from U.S. Army Medical Research Acquisition Activity to develop wearable biosensors

  The Lundquist Institute has been awarded a four-year, $2.6 million grant to develop wearable multiplex biosensors that can monitor exacerbation risk in COPD. The proposed sensors have the potential to revolutionize COPD management and transform chronic disease management by providing real-time, non-invasive monitoring.

• The Lundquist Institute · Oct 30, 2025 The Lundquist Institute awarded $9 million to launch Community Center of Excellence for Regenerative Medicine

  The Lundquist Institute has been awarded $9 million by the California Institute for Regenerative Medicine (CIRM) to establish a Community Center of Excellence for Regenerative Medicine. This center will expand access to cutting-edge regenerative therapies and create skilled healthcare professionals in underserved communities.

• The Lundquist Institute · Apr 7, 2025 New research from The Lundquist Institute finds ketogenic diet-induced high cholesterol does not predict heart disease

  A new study from The Lundquist Institute found no association between plaque progression and LDL-C levels, suggesting that high cholesterol is not a marker of cardiovascular risk. Metabolically healthy individuals on a ketogenic diet with elevated LDL-C levels have a unique metabolic profile that requires personalized risk assessment.

• The Lundquist Institute · Jul 15, 2025 The Lundquist Institute wins multi-year NIH grant exceeding $11 million to transform diagnosis and treatment of deadly mucormycosis

  The Lundquist Institute has received a $11 million NIH grant to revolutionize the diagnosis and treatment of mucormycosis, a deadly fungal infection. The MUCOR-ADVANCE initiative aims to develop rapid diagnostic tests and immune-based therapies to save lives.

• The Lundquist Institute · Dec 15, 2025 The Lundquist Institute and its start-up company Vitalex Biosciences Announces Strategic Advancement of Second-Generation fungal Vaccine VXV-01 through Phase 1 Trials under $40 Million Competitive Contract from NIH/NIAID

  The Lundquist Institute's second-generation fungal vaccine candidate, VXV-01, is moving forward in development after securing a $40 million NIH/NIAID contract. The vaccine aims to elicit robust immunity against opportunistic and hospital-associated pathogens.